Date: 2015-01-07
Type of information: Nomination
Compound:
Company: Anthera Pharmaceuticals (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 7, 2015, Anthera Pharmaceuticals announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer. Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics\' initial product, Ravicti® (glycerol phenylbutyrate) Oral Liquid for chronic management of adult and pediatric patients > 2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix\'s initial product, Ventavis ® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Financial terms:
Latest news:
